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Abstract
Background: We previously showed that the burden of Chlamydia pneumoniae in carotid plaques was significantly
associated with plaque interleukin (IL)-6, and serum IL-6 and C-reactive protein (CRP), suggesting that infected plaques
contribute to systemic inflammatory markers in patients with stroke risk. Since lipoprotein-associated phospholipase A2 (Lp-
PLA2) mediates inflammation in atherosclerosis, we hypothesized that serum Lp-PLA2 mass and activity levels and plaque
Lp-PLA2 may be influenced by plaque C. pneumoniae infection.
Methodology/Principal Findings: Forty-two patients underwent elective carotid endarterectomy. Tissue obtained at
surgery was stained by immunohistochemistry for Lp-PLA2 grade, macrophages, IL-6, C. pneumoniae and CD4+ and CD8+
cells. Serum Lp-PLA2 activity and mass were measured using the colorimetric activity method (CAM
TM) and ELISA,
respectively. Serum homocysteine levels were measured by HPLC. Eleven (26.2%) patients were symptomatic with transient
ischemic attacks. There was no correlation between patient risk factors (smoking, coronary artery disease, elevated
cholesterol, diabetes, obesity, hypertension and family history of genetic disorders) for atherosclerosis and serum levels or
plaque grade for Lp-PLA2. Plaque Lp-PLA2 correlated with serum homocysteine levels (p=0.013), plaque macrophages
(p,0.01), and plaque C. pneumoniae (p,0.001), which predominantly infected macrophages, co-localizing with Lp-PLA2.
Conclusions: The significant association of plaque Lp-PLA2 with plaque macrophages and C. pneumoniae suggests an
interactive role in accelerating inflammation in atherosclerosis. A possible mechanism for C. pneumoniae in the atherogenic
process may involve infection of macrophages that induce Lp-PLA2 production leading to upregulation of inflammatory
mediators in plaque tissue. Additional in vitro and in vivo research will be needed to advance our understanding of specific
C. pneumoniae and Lp-PLA2 interactions in atherosclerosis.
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Introduction
Carotid atherosclerosis is a major risk factor for an ischemic
stroke [1]. While lipid metabolism and inflammation have been
the major focus of atherosclerosis research for many years, there
has been a growing interest in lipoprotein-associated phospholi-
pase A2 (Lp-PLA2) because it is a key enzyme both in lipid
metabolism and in stimulating inflammation [2].
Lp-PLA2 is a calcium-independent member of the phospholi-
pase A2 enzyme family. Monocytes, macrophages, T-lymphocytes,
mast cells and liver cells are the main sources for Lp-PLA2 [3,4]. It
is carried primarily by low-density lipoprotein (LDL). Lp-PLA2
catalyzes the hydrolysis of oxidized LDL, which produces
proinflammatory mediators lysophosphatidylcholine (LysoPC)
and oxidized fatty acid (oxFA) [5].
Many clinical studies have found an association between
increasing serum levels of Lp-PLA2 mass and/or activity at the
time of a cardiovascular incident in addition to an elevated risk of
mortality and morbidity over time [6,7,8]. One study showed that
Lp-PLA2 mRNA and protein levels were six times higher in
atherosclerotic lesions compared to normal tissue samples [9].
Cumulative evidence suggests that C. pneumoniae also plays an
important role in atherosclerosis [10,11,12,13,14]. The organism
is thought to infect pulmonary monocytes that are then
transported via the vasculature to localize in arteries where
infection can spread [15]. C. pneumoniae is a ubiquitous pathogen
that frequently causes upper and lower respiratory tract infections
worldwide [16]. More than half of the patients with atherosclerosis
have evidence for C. pneumoniae infection based on a variety of
studies using detection methods such as immunohistochemistry
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time RT-PCR of DNA/RNA extracted from plaques [18,19,21],
and seroepidemiologic analyses among different populations
[20,21]. Other studies have shown viable organisms in the carotid
arteries of stroke patients [19,22] and patients with CAD [11,23].
Furthermore, recent studies in murine and rabbit models suggest
that C. pneumoniae can target the vasculature, induce inflammation
and initiate or promote the development of atherosclerosis
[14,24,25]. In the same models, C. pneumoniae accelerated
atherosclerotic development, while treatment with azithromycin
prevented the disease [12,14]. However, treatment did not have
the same effect on chronically infected mice [26], where organism
persistence may have contributed to resistance to therapy. Recent
in vitro studies also strongly suggest a role for C. pneumoniae in the
genesis and progression of atherosclerosis [27,28]
More recently, we have shown that the burden of C. pneumoniae
infection was significantly associated with up-regulation of plaque
interleukin (IL)-6 expression, which correlated with elevated serum
levels of IL-6 and C-reactive protein (CRP) [18]. IL-6 stimulates
liver CRP production, an acute phase reactant associated with risk
of myocardial infarction (MI) and stroke. IL-6 secretion in C.
pneumoniae-infected plaques could explain elevated systemic
markers of inflammation among individuals at risk for vascular
events.
There is currently no research, to our knowledge, correlating
serum Lp-PLA2 mass and activity levels with plaque Lp-PLA2 or
the interaction of C. pneumoniae infection and Lp-PLA2 on arterial
disease and inflammation. We hypothesized that serum Lp-PLA2
mass and activity levels as well as plaque Lp-PLA2 would be
significantly elevated in the presence of plaque C. pneumoniae
infection, suggesting an interactive role in accelerating inflamma-
tion in atherosclerosis.
Materials and Methods
Ethics Statement
The University of California at San Francisco (UCSF) and
Children’s Hospital Oakland Research Institute (CHRCO)
Institutional Review Board committees approved the study.
Informed written consent was obtained for all study subjects.
The study was conducted according to the principles of the
Declaration of Helsinki.
Study subjects
In this cross-sectional study, subjects underwent elective carotid
endarterectomy at UCSF, as described previously [19]. The
treated carotid artery was associated with signs and/or symptoms
of neurologic disease.
Lipoprotein-associated phospholipase A2 (Lp-PLA2)
detection by immunohistochemistry (IHC) in carotid
artery tissue
Lp-PLA2 was detected by IHC using three, five-micron sections
per carotid plaque in optimal cutting temperature (OCT) medium.
The carotid plaque tissue was stored at 280uC in OCT until
sectioning. Briefly, each section was blocked with casein (Biocare
Medical, Concord, CA) and stained with anti-Lp-PLA2 monoclo-
nal antibody (diaDexus, Inc., South San Francisco, CA) diluted
1:400 in diluent (Biocare). Samples were washed with TBS,
blocked with avidin (Biocare), washed again and blocked with
biotin (Biocare) prior to applying goat, anti-mouse IgG antibody
(Biocare). Streptavidin was applied followed by alkaline phospha-
tase chromagen-fast red (Biocare). The section was counterstained
with hematoxylin to detect each cell. In independent experiments,
excess primary antibody and, separately, excess secondary
antibody was used on adjacent sections to ensure no non-specific
staining of either antibody for Lp-PLA2. In addition, a mouse non-
immune IgG (Biocare) was used as a final negative control.
Using light microscopy at 4006, samples were read indepen-
dently by two individuals who were blinded to all patient data.
Samples were graded based on percentage of the tissue staining for
Lp-PLA2 for the entire plaque section. We used 1, 2 or 3+ for the
entire carotid section for each patient sample (3 sections per
patient carotid sample) where a grade of $1 was considered
positive for Lp-PLA2; 1, 1–25% of the tissue; 2, 26–50% of the
tissue; 3, .50% of the tissue. The three sections from each carotid
sample were used to determine the within-sample variation, and
the average of the three was used for analysis. Because of the ease
of visualization of the staining for Lp-PLA2 (see Fig 1A), software
was not required for quantitation.
All sections that stained positive for Lp-PLA2 were probed with
chlamydial-specific heat shock protein 60 (CHsp60) MAb (Affinity
Bioreagents) to determine the precise co-localization of Lp-PLA2
and infection using the methods as described above except that a
horseradish peroxidase–conjugated secondary antibody with
chromogen diaminobenzidine (DAB; Biocare) was used to detect
chlamydiae. Positive and negative controls were as described
previously [18,19]. All three sections for each patient were read in
entirety and analyzed as described for Lp-PLA2 except that the
cells were counted to determine the number with Lp-PLA2 alone,
C. pneumoniae alone, and the number with both for each section as
quantitative measures.
Two additional adjacent sections for each patient sample were
used to co-localize C. pneumoniae with macrophages. The sections
were stained for C. pneumoniae as above, and macrophages were
stained with fast red as for Lp-PLA2 except that the primary
monoclonal antibody was macrophage specific (CD68; Biocare).
While other infectious agents may also be involved in
atherosclerosis, the evaluation of these pathogens was beyond
the scope of this study.
Prior data on the patient population used for analyses
In our prior studies, plaque tissues were noted to have a high
grade of atherosclerosis [18,19]. Data on the same population
from our previous publications were also used for analyses [18,19].
These included IHC to detect macrophages, CD4+ cells, CD8+
cells, IL-6, and C. pneumoniae in the adjacent sections of the same
block of carotid tissue used for Lp-PLA2 IHC above. In addition,
we previously determined plaque IL-6 gene expression by
quantitative (q)RT-PCR, plaque C. pneumoniae burden by qRT-
PCR, serum C-reactive protein (CRP) levels, and IL-6 serum
protein levels, the methods of which are described in detail in our
references [18,19].
Measurement of serum mass and activity levels for
lipoprotein-associated phospholipase A2 (Lp-PLA2) and
homocysteine levels
All serum biochemical analyses were performed on serum from
blood or blood plasma obtained at the time of carotid
endarterectomy.
Lp-PLA2 mass was determined by ELISA (PLACH Test;
diaDexus) in serum according to the manufacturers instructions
using two specific monoclonal antibodies in a 96-well format.
Quantitation was calibrated to a recombinant Lp-PLA2 antigen
standard. The lower detection limit was 2 ng/mL; interassay
coefficient of variation (CV) was between 6% and 7%. Lp-PLA2
activity levels were measured by CAM
TM assay (diaDexus) in
Plaque Lp-PLA2 & C. pneumoniae
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analyzed in a 96-well microplate with a colorimetric substrate
converted on hydrolysis by phospholipase enzyme. Briefly, 25 mL
of sample, standard, or control was added per well, followed by
addition of assay buffer plus substrate. Change in absorbance was
measured at 405 nm. Lp-PLA2 activity in nmol/min/mL was
calculated from the slope, based on a standard conversion factor
from a p-Nitrophenol calibration curve. Activity levels between
13.5–46.1 were considered as quartile-1, 46.2–69 as quartile-2,
69.1–89.2 as quartile-3, and 89.3–143.2 as quartile-4.
Homocysteine levels in serum (the preferred sample type) were
measured by fluorometric high-performance liquid chromatogra-
phy (HPLC; Quest Diagnostics).
Statistical analysis
Clinical and laboratory characteristics of patients were com-
pared by serum Lp-PLA2 mass and activity levels and Lp-PLA2
plaque grade. Before comparing continuous variables for Lp-PLA2
plaque grades, the normality assumption was checked by Shapiro-
Wilk test and the distributional diagnostic plots for these variables:
age, Lp-PLA2 serum activity, and homocysteine levels. All except
homocysteine had a normal distribution. Square root transforma-
tion of homocysteine levels was performed to achieve the
normality assumption.
Student t-test was used to compare plaque Lp-PLA2 positive vs.
negative groups for continuous variables with normal distribution.
Pearson chi-square test was used to compare plaque Lp-PLA2
positive vs. negative groups for binomial variables: history of
smoking, coronary artery disease, elevated cholesterol, diabetes,
obesity, hypertension and family history of genetic disorders,
elevated serum CRP, serum IL-6, C. pneumoniae by qRT-PCR and
plaque IL-6, CD4+, CD8+, macrophages, and C. pneumoniae.
Multiple logistic regression was also performed for these
comparisons, including all variables associated with Lp-PLA2 (at
p,0.20) with a stepwise removal of any that did not contribute (at
p.0.10). Since Lp-PLA2 serum activity results were categorized
into four quartiles, Kruskal-Wallis test was used for comparing
serum Lp-PLA2 quartiles for clinical characteristics. Nonparamet-
ric Spearman Rank test was used to calculate correlation
coefficients between variables with Bonferroni adjustment. A P
Figure 1. Carotid plaque sections showing co-localization of Lp-PLA2 and C. pneumoniae, and macrophages and C. pneumoniae. A)
Lipoprotein-associated phospholipase A2 (Lp-PLA2) was detected by Immunohistochemistry (IHC) using anti- Lp-PLA2 specific monoclonal antibody
(diaDexus) and chromagen fast red (arrowheads); C. pneumoniae was detected by IHC using a CHsp60-specific MAb and chromagen DAB (arrows);
61000. B) Negative control of a positive carotid plaque section (same patient as in A);61000. C) Carotid plaque section showing co-localization of C.
pneumoniae (DAB; arrows) and macrophages detected by IHC using CD68 macrophage-specific monoclonal antibody and chromagen fast red
(arrowheads); 61000. D) Negative control of a positive carotid plaque section (same patient as in C).
doi:10.1371/journal.pone.0011026.g001
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version-9 (College Station, TX) was used for all analyses.
Results
Patient characteristics and association with serum Lp-
PLA2 activity and plaque Lp-PLA2
Characteristics of the 42 study patients are shown in Tables 1
and 2 stratified by Lp-PLA2 plaque status and Lp-PLA2 serum
activity, respectively. We considered the 42 patients to be a
representative cohort of patients with neurologic signs and/or
symptoms consistent with carotid vascular disease in addition to
the fact that they were enrolled consecutively after informed
consent from the pre-operative evaluation clinic at UCSF as
previously described [18,19]. None of the patients had stroke but
all had neurologic symptoms, indicating carotid ischemia: 30
(71.4%) had symptoms on the left side, 11 (26.2%) on the right,
and 1 (2.4%) bilaterally. It should be noted that the treated carotid
artery was associated with symptoms on the ipsilateral side. There
were no significant correlations of risk factors (smoking, coronary
artery disease, elevated cholesterol, diabetes, obesity, hypertension
and family history of genetic disorders) or clinical characteristics
with Lp-PLA2 serum levels or tissue Lp-PLA2 grade $1 (Tables 1
and 2) or with C. pneumoniae infection as defined by qRT-PCR or
IHC as described previously [18,19] (Tables 3 and 4).
Correlation among carotid plaque characteristics and
serum levels of inflammatory markers
Serum Lp-PLA2 mass and activity levels were significantly
correlated (r=0.76, p=0.001, Table 3). High Lp-PLA2 activity
was also correlated with Lp-PLA2 mass (r3=0.37 and r4=0.48,
p3=0.015 and p4=0.001, respectively, Table 4).
Interestingly, 94.7% (18/19) of patients who had plaque Lp-
PLA2 also had plaque C. pneumoniae. Plaque Lp-PLA2 presence (for
all quantitative grades above 1) was significantly correlated with C.
pneumoniae (r=0.39, p=0.001) and macrophages (r=0.37,
p=0.01, Table 3), and with higher serum homocysteine levels
(r=0.38, p=0.013, Table 3). Plaque Lp-PLA2 co-localized with C.
pneumoniae, macrophages and CD4+ lymphocytes by IHC in the
shoulder and necrotic core of the plaques as has been noted by
others [9]. We found that 52% of cells showed evidence for Lp-
PLA2 protein and infection with C. pneumoniae (Figure 1A). In
addition, 39% of macrophages were infected with C. pneumoniae
(Figure 1B).
In Table 3, the correlation between carotid plaque Lp-PLA2
and plaque IL-6 expression, IL-6 detected by IHC, serum IL-6,
and CRP was statistically insignificant for all plaque Lp-PLA2
grades. Serum Lp-PLA2 mass levels were negatively correlated
with plaque IL-6 expression and IL-6 detected by IHC (r=20.31,
p=0.048; r=20.34, p=0.03, respectively), and not correlated
with serum IL-6 or CRP. Serum Lp-PLA2 activity levels were
negatively correlated with IL-6 detected by IHC (r=20.32,
p=0.04) and not correlated with plaque IL-6 expression, serum
IL-6 or CRP.
Figure 2A shows staining of Lp-PLA2 (red) in the perivascular
necrotic area of carotid plaque. This region was rich in
macrophages in addition to C. pneumoniae infected macrophages.
Figure 2B shows the adjacent section stained with secondary
antibody and omission of primary antibody against Lp-PLA2 as a
control for specificity. There were similar results for staining with
the control mouse non-immune IgG antibody (data not shown).
Discussion
This is the first study, to our knowledge, that evaluates the
correlation between Lp-PLA2 serum mass and activity levels with
presence of Lp-PLA2 in carotid plaques, and the association of
these indicators with plaque C. pneumoniae and other inflammatory
mediators. Lp-PLA2 serum mass and activity levels correlated well
with one another but not with plaque Lp-PLA2. However, plaque
Lp-PLA2 was significantly correlated with plaque C. pneumoniae
infection, macrophages and serum homocysteine levels. A high
percentage of macrophages were infected, and many cells showed
co-localization of Lp-PLA2 with C. pneumoniae. Thus, a possible
mechanism for C. pneumoniae in the atherogenic process may
involve infection of macrophages that induce Lp-PLA2 production
Table 1. Clinical characteristics of study population by plaque Lp-PLA2.
a
Characteristics Total (n=42)
Plaque Lp-PLA2
negative (n=23)
Plaque Lp-PLA2
positive (n=19) P Value
b
Age (mean +/2 s.d.) 72 (9.4) 72.4 (+/210.6) 72.3 (+/28) 0.987
Sex: 0.327
Male 30 (71.4%) 15 (65.2%) 15 (78.9%)
Female 12 (28.6%) 8 (34.8%) 4 (21.1%)
Smoker 33 (78.6%) 17 (73.9%) 16 (84.2%) 0.418
CAD 23 (54.8%) 11 (47.8%) 12 (63.2%) 0.320
Hypertension history 36 (85.7%) 20 (87%) 16 (84.2%) 0.800
High cholesterol 27 (64.3%) 14 (60.8%) 13 (68.4%) 0.611
Diabetes mellitus 9 (21.4%) 4 (17.4%) 5 (26.3%) 0.483
Symptomatic 0.264
Left side 30 (71.4%) 18 (78.3%) 12 (63.2%)
Right side 11 (26.2%) 4 (17.4%) 7 (63.7%)
Both 1 (2.4%) 1 (4.3%) 0
Abbreviations: Lp-PLA2, Lipoprotein-associated phospholipase A2; CAD, Coronary Artery Disease.
aValues expressed are for plaque Lp-PLA2 grade of $1 as the results were the same for any grade $1.
bP values were generated by chi-square test except for age, where t-test was used for comparison.
doi:10.1371/journal.pone.0011026.t001
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tissue.
We found no significant correlation between patient risk factors
for atherosclerosis and serum levels or plaque grade for Lp-PLA2
in our study. Our findings are similar to those of others [29] but in
contrast to some publications that reported a correlation between
clinical characteristics or risk factors and serum Lp-PLA2 mass or
activity levels [30,31]. Earlier publications initially found strong
correlations between serum Lp-PLA2 levels and clinical charac-
teristics, which decreased significantly after adjustment for
Table 2. Clinical characteristics of study population by serum Lp-PLA2 activity.
a
Characteristics
Lp-PLA2 Activity 1
st
quartile (n=10)
c
Lp-PLA2 Activity 2
nd
quartile (n=10)
c
Lp-PLA2 Activity 3
rd
quartile (n=10)
c
Lp-PLA2 Activity 4
th
quartile (n=11)
c P Value
b
Age (mean +/2 s.d.) 67.9 (+/210.1) 71 (+/210.1) 75.9 (+/27.8) 73.7(+/28.5) 0.519
Sex: 0.403
Male (n=29
b) 8 (27.6%) 5 (17.2%) 8 (27.6%) 8 (27.6%)
Female (n=12
b) 2 (17%) 5 (41%) 2 (17%) 3 (25%)
Smoker 8 (25%) 7 (21.9%) 6 (25%) 11 (28.1%) 0.916
CAD 2 (9.1%) 7 (31.8%) 6 (27.3%) 7 (31.8%) 0.101
Hypertension 7 (20%) 9 (25.7%) 8 (22.9%) 11 (31.4%) 0.243
High cholesterol 4 (15.4%) 8 (30.8%) 5 (19.2%) 9 (34.6%) 0.115
Diabetes mellitus 3 (33.3%) 1 (11.1%) 1 (11.1%) 4 (44.5%) 0.337
Symptomatic: 0.095
Right side 9 (31%) 7 (24.2%) 4 (13.8%) 9 (31%)
Left side 1 (9.1%) 2 (18.2%) 6 (54.6%) 2 (18.2%)
Both sides 0 1 (100%) 0 0
Abbreviations: Lp-PLA2, Lipoprotein-associated phospholipase A2; Lp-PLA2.
Activity, range measured in nmol/min/mL; CAD, Coronary Artery Disease.
aLp-PLA2 Activity range measured in nmol/min/mL.
bP values were generated by chi-square test except for age, where t-test was used for comparison.
cSerum Lp-PLA2 activity information was missing for one person.
doi:10.1371/journal.pone.0011026.t002
Table 3. Correlations among plaque characteristics and serum levels of inflammatory markers.
Carotid Plaque Lp-PLA2 Serum Lp-PLA2 mass (ng/mL) Serum Lp-PLA2 activity
Carotid Plaque
Cpn by qRT-PCR 0.21 20.28 20.23
Cpn by IHC 0.39
a 20.24 20.08
IL-6 expression 0.23 20.31
d 20.22
IL-6 by IHC 0.11 20.34
d 20.32
d
Macrophages 0.37
b 0.06 0.11
CD4+ 0.17 20.04 20.13
CD8+ 20.02 20.10 20.13
B-cell 20.11 20.22 20.32
Lp-PLA2 1 0.14 0.19
Serum
Lp-PLA2 mass (ng/mL) 0.14 1 0.76
a
Lp-PLA2 activity 0.19 0.76
a 1
CRP 0.18 20.25 20.21
IL-6 0.08 20.27 20.19
Homocysteine 0.38
c 20.006 0.12
Abbreviations: Lp-PLA2, Lipoprotein-associated phospholipase A2; Cpn, C. pneumoniae; qRT-PCR, quantitative real-time reverse transcription PCR; IL-6, interleukin-6; IHC,
immunohistochemistry; CRP, C-reactive protein.
ap,0.001.
bp,0.01.
cp,0.013.
dp,0.05.
doi:10.1371/journal.pone.0011026.t003
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correlation between either clinical characteristics or risk factors
and Lp-PLA2 might be explained by the small sample size.
However, serum Lp-PLA2 mass and activity levels may not be
consistently reliable risk markers for atherosclerosis.
There is prior evidence that both serum Lp-PLA2 mass and
activity levels are influenced by infection such as hepatitis C,
malaria and influenza [34,35,36]. For example, malaria research-
ers have shown a positive correlation between circulating levels of
Lp-PLA2, parasitemia and severity of disease [35]. Studies of the
interrelationship of influenza with inflammatory responses and
atherosclerosis were initiated based on the observation of a strong
association between acute respiratory infections, acute MI and
sudden death in winter [36]. In a murine model of influenza, Lp-
PLA2 activity in high density lipoproteins (HDL) was found to
decrease two days after inoculation of influenza, reaching the
lowest levels within a week, while Lp-PLA2 modification of LDL
and lipid peroxide products increased as monocyte migration was
induced [36].
In our study, only plaque Lp-PLA2, but not serum Lp-PLA2
mass or activity levels, was significantly associated with the
presence of C. pneumoniae. Prior studies have shown that persistent
C. pneumoniae infection, characterized by up-regulation of chla-
mydial heat shock protein 60 expression, induced LDL oxidation
that leads to macrophage activation [37]. It is well known that
oxidized LDL is also a substrate of Lp-PLA2 catalyzed reactions,
resulting in LysoPC and oxFA [5]. LysoPC induces proinflamma-
tory cytokines and chemokines, such as IL-1b, IL-6, TNF-a, and
monocyte chemoattractant protein 1 (MCP-1) [38]. IL-1b, IL-6
and TNF-a trigger atherogenesis by sensitizing vascular smooth
muscle cells [39] and inducing secretion of cellular adhesion
molecules [40] and matrix metalloproteinase (MMP) by mono-
cytes during later stages of atherosclerosis [41]. MCP-1 recruits T
cells and monocytes, inhibits endothelial nitric oxide (causing
endothelial dysfunction), induces monocyte-macrophage colony-
stimulating factor (M-CSF) secretion by smooth muscle cells and
stimulates macrophage proliferation [42,43,44]. In our study, we
found that plaque Lp-PLA2 was significantly correlated with
plaque macrophages, which is consistent with these studies.
Several studies have shown that C. pneumoniae activated
macrophages induce pro-inflammatory cytokine/chemokines,
such as IL-6, IL-8 and MCP-1 [18,45,46]. In our previous
evaluation of the same tissue samples as in the present study, we
found that macrophages in the carotid plaques co-localized with
CD4+ lymphocytes [18], which can secrete pro-inflammatory
cytokines and further fuel the atherogenic process. Both CD4+
cells and macrophages release interferon gamma (IFN-c), which
can resolve chlamydial infection or stimulate a non-replicative
persistent state that can result in chronic infection that is likely
resistant to antimicrobial treatment.
IL-6 is an acute phase reactant secreted by activated
macrophages, Th2 cells and B cells. We previously showed that
Table 4. Correlations between serum Lp-PLA2 activity, and plaque and serum Lp-PLA2 mass.
Serum Lp-PLA2 activity
(range in nmol/min/mL) Plaque Lp-PLA2
a Serum Lp-PLA2 mass (ng/mL)
1
st quartile (13–46.1) 0.04 (p=0.822) 20.47 (p,=0.001)
2
nd quartile (46.2–69) 20.14 (p=0.375) 20.31 (p=0.043)
3
rd quartile (69.1–89.2) 0.02 (p=0.987) 0.37 (p=0.015)
4
th quartile (89.3–143.2) 0.13 (p=0.417) 0.48 (p=0.001)
Abbreviations: Lp-PLA2, Lipoprotein-associated phospholipase A2.
aValues expressed are for plaque Lp-PLA2 grade of $1 as there were no significant correlations with grades .1.
doi:10.1371/journal.pone.0011026.t004
Figure 2. Carotid plaque section from a patient with atherosclerosis. A) Lipoprotein-associated phospholipase A2 (Lp-PLA2) was detected by
Immunohistochemistry (IHC) using anti- Lp-PLA2 specific monoclonal antibody (diaDexus) and chromagen fast red; 4006. B) The five micron adjacent
carotid plaque section from the same patient was stained as in A but the primary antibody was omitted as a control for specificity; 4006.
doi:10.1371/journal.pone.0011026.g002
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measured by qRT-PCR and semi-quantitative IHC was associated
with higher IL-6 expression in both plaques and serum [18].
Subsequent studies have also shown that atherosclerotic progres-
sion, based on intima-media wall thickness, was associated with
higher serum IL-6 levels among C. pneumoniae patients [47]. In in
vitro studies, C. pneumoniae induces the production of IL-6 in
peripheral monocytes and smooth muscle cells [45]. Neither serum
nor plaque IL-6 correlated with serum Lp-PLA2 activity or mass
levels or with plaque Lp-PLA2 grade in our study. However, one
other study also failed to show a correlation between serum IL-6
and Lp-PLA2 activity [48]. This might be due to the indirect
pathways induced by Lp-PLA2 where the temporal influence of
Lp-PLA2 and up-regulation of serum IL-6 are missed because only
a single serum sample is obtained at the time of endartectomy.
Similarly, given that we found a lack of association of serum Lp-
PLA2 mass or activity levels with plaque Lp-PLA2 and with plaque
C. pneumoniae, it is possible that either the timing of sample
collection yields a false negative result or that what is occurring
locally in the tissue does not always reflect the circulating systemic
levels of Lp-PLA2. Thus, some patients may not express elevated
serum Lp-PLA2 levels in association with risk factors or disease
[32,33] or with infection.
There was a significant correlation of plaque Lp-PLA2 with
serum homocysteine levels. Homocysteine exerts an independent
effect on vascular smooth muscle cell proliferation, although the
mechanism(s) is not well understood [49]. It is unclear from our
data whether there is a direct interaction between homocysteine
and plaque Lp-PLA2 that may accelerate atherosclerotic progres-
sion.
Overall, we found that macrophages, many of which were
infected with C. pneumoniae, co-localized with Lp-PLA2. A high
percentage of cells demonstrated co-localization of Lp-PLA2 and
C. pneumoniae. These findings suggest that macrophages may be
activated by C. pneumoniae infection, inducing Lp-PLA2 production
and subsequent proinflammatory mediators, and, under the
influence of Lp-PLA2 byproducts, result in macrophage prolifer-
ation that in turn release inflammatory mediators. This scenario
indicates a possible indirect mechanism for C. pneumoniae
involvement in the atherogenic process. However, additional
research focused on in vitro cell and in vivo animal models will be
needed to advance our understanding of the interaction of C.
pneumoniae infection with Lp-PLA2 in inflammation and athero-
sclerotic disease.
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